Analyst Reco. CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-23 pm EDT			5-day change	1st Jan Change
56.41 ^USD	+1.35%		-2.67%	-9.89%

Apr. 18	Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	MT
Apr. 17	Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	Apr. 18	MT
Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	Apr. 17	MT
Mizuho Adjusts Price Target on CRISPR Therapeutics to $99 From $82, Maintains Buy Rating	Mar. 06	MT
Morgan Stanley Adjusts Price Target on CRISPR Therapeutics to $48 From $46, Maintains Underweight Rating	Feb. 26	MT
Wells Fargo Raises Price Target on CRISPR Therapeutics to $70 From $55, Maintains Equal-Weight Rating	Feb. 22	MT
Barclays Raises Price Target on CRISPR Therapeutics to $80 From $61, Maintains Equal-Weight Rating	Feb. 22	MT
Chardan Ups Price Target on CRISPR Therapeutics to $112 From $110, Keeps Buy Rating	Feb. 22	MT
RBC Raises Price Target on CRISPR Therapeutics to $66 From $57 on Strengthened Balance Sheet, Casgevy Approval; Sector Perform, Speculative Risk Kept	Feb. 22	MT
Needham Adjusts CRISPR Therapeutics' Price Target to $90 From $88, Keeps Buy Rating	Feb. 21	MT
Wolfe Research Starts Coverage on CRISPR Therapeutics With Peer Perform Rating	Feb. 15	MT
Kempen Downgrades CRISPR Therapeutics to Neutral From Buy, Cuts Price Target to $65 From $80	Dec. 22	MT
Morgan Stanley Lifts Price Target on CRISPR Therapeutics to $46 From $42, Keeps Underweight Rating	Dec. 12	MT
Truist Securities Adjusts Price Target on CRISPR Therapeutics to $160 From $220, Maintains Buy Rating	Dec. 11	MT
Needham Raises CRISPR Therapeutics' Price Target to $88 From $85, Keeps Buy Rating	Dec. 11	MT
Barclays Raises Price Target on CRISPR Therapeutics to $61 From $56, Maintains Equalweight Rating	Dec. 11	MT
TD Cowen Downgrades CRISPR Therapeutics to Underperform From Market Perform, $30 Price Target	Dec. 11	MT
RBC Lifts Price Target on CRISPR Therapeutics to $57 From $50 After US FDA Approval of CASGEVY for Sickle Cell Disease; Sector Perform, Speculative Risk Kept	Dec. 11	MT
JMP Securities Raises Price Target on CRISPR Therapeutics to $80 From $74, Keeps Market Outperform Rating	Dec. 11	MT
Joe Biden and Xi Jinping almost made up	Nov. 16
Morgan Stanley Trims Price Target on CRISPR Therapeutics to $42 From $43, Keeps Underweight Rating	Nov. 13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Analyst Reco.

Filters